Publications 2025
Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors
Eur J Med Chem, 288, 117397
DOI 10.1016/j.ejmech.2025.117397, PubMed 39983556
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization
J Med Chem (in press)
DOI 10.1021/acs.jmedchem.4c02845, PubMed 40134122
Publications 2022
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models
Cancer Res Commun, 2 (4), 233-245
DOI 10.1158/2767-9764.CRC-22-0027, PubMed 36873622
Publications 2021
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
J Med Chem, 64 (24), 17936-17949
DOI 10.1021/acs.jmedchem.1c01264, PubMed 34878777
Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines
iScience, 24 (7), 102807
DOI 10.1016/j.isci.2021.102807, PubMed 34337362
Publications 2020
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
Commun Biol, 3 (1), 196
DOI 10.1038/s42003-020-0916-2, PubMed 32332858